Neal D Shore, Christian Gratzke, Susan Feyerabend, Patrick Werbrouck, Joan Carles, Egils Vjaters, Teuvo L J Tammela, David Morris, Jeanny B Aragon-Ching, Raoul S Concepcion, Urban Emmenegger, Neil Fleshner, Markus Grabbert, Vilnis Lietuvietis, Hakim Mahammedi, Felipe M Cruz, Adriano Paula, Christopher Pieczonka, Antti Rannikko, Martin Richardet, Glauco Silveira, Iris Kuss, Marie-Aude Le Berre, Frank Verholen, Toni Sarapohja, Matthew R Smith, Karim Fizazi
BACKGROUND: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) are usually asymptomatic and seek treatments that improve survival but have a low risk of adverse events. Darolutamide, a structurally distinct androgen receptor inhibitor (ARi), significantly reduced the risk of metastasis and death versus placebo in ARAMIS. We assessed the extended safety and tolerability of darolutamide and the time-course profile of treatment-emergent adverse events (TEAEs) related to ARis and androgen-suppressive treatment...
February 23, 2024: Oncologist